| Literature DB >> 19505310 |
Felix C Ringshausen1, Stephan Schlösser, Albert Nienhaus, Anja Schablon, Gerhard Schultze-Werninghaus, Gernot Rohde.
Abstract
BACKGROUND: Smear-negative pulmonary tuberculosis (TB) accounts for a considerable proportion of TB transmission, which especially endangers health care workers (HCW). Novel Mycobacterium-tuberculosis-specific interferon-gamma release assays (IGRAs) may offer the chance to define the burden of TB in HCW more accurately than the Mantoux tuberculin skin test (TST), but the data that is available regarding their performance in tracing smear-negative TB in the low-incidence, in-hospital setting, is limited. We conducted a large-scale, in-hospital contact investigation among HCW of a German university hospital after exposure to a single case of extensive smear-negative, culture-positive TB with pulmonary involvement. The objective of the present study was to evaluate an IGRA in comparison to the TST and to identify risk factors for test positivity.Entities:
Year: 2009 PMID: 19505310 PMCID: PMC2698921 DOI: 10.1186/1745-6673-4-11
Source DB: PubMed Journal: J Occup Med Toxicol ISSN: 1745-6673 Impact factor: 2.646
Figure 1Study profile. HCW = health care workers; IGRA = interferon-γ release assay. PCT = preventive chemotherapy; PPD = purified protein derivate; QFT-GIT = QuantiFERON®-TB Gold in Tube; TST = tuberculin skin test.
Characteristics of the study population
| Variables | n | % |
| Subjects, total | 143 | 100 |
| Sex | ||
| Male | 44 | 30.8 |
| Female | 99 | 69.2 |
| Age categorized* | ||
| 18 to 39 years | 84 | 58.7 |
| 40 to 49 years | 36 | 25.2 |
| ≥ 50 years | 23 | 16.1 |
| Duration of employment in health care* | ||
| 1 to 5 years | 35 | 24.5 |
| 6 to 10 years | 25 | 17.5 |
| 11 to 20 years | 50 | 35.0 |
| 21 to 42 years | 33 | 23.1 |
| Foreign country of birth† | ||
| Yes | 25 | 17.5 |
| No | 118 | 82.5 |
| Birth in high burden country‡ | 4 | 2.8 |
| BCG vaccination | ||
| Yes | 73 | 51.0 |
| No | 56 | 39.2 |
| unknown | 14 | 9.8 |
| Cumulative exposure time | ||
| ≤ 1 hour | 76 | 53.1 |
| > 1 to 8 hours | 42 | 29.4 |
| > 8 to 40 hours | 21 | 14.7 |
| > 40 hours | 4 | 2.8 |
| Close contact | 82 | 57.3 |
| Prior TST | 117 | 81.8 |
| Positive prior TST result | 45 | 38.5 |
| TST >5 mm induration | 40 | 28.0 |
| TST >10 mm induration | 28 | 19.6 |
| Positive QFT-GIT result | 13 | 9.1 |
| Health care professions | ||
| Nursing | 49 | 34.3 |
| Physician | 24 | 16.8 |
| Other | 70 | 49.0 |
| Affiliation with Pulmonary Care | 18 | 12.6 |
| Own history of TB | 1 | 0.7 |
| Family history of TB | 8 | 5.6 |
* Age and duration of employment were highly correlated (r = 0.72, p < 0.001). † Mostly Poland (n = 9) and Turkey (n = 7). ‡ TB high burden countries (according to WHO [1]): Morocco (n = 2), Philippines (n = 1), Bosnia and Herzegovina (n = 1). BCG = Bacillus Calmette-Guérin; TB = tuberculosis; TST = tuberculin skin test.
Figure 2Frequencies of positive test results. Frequencies of recent positive test results (%) are displayed depending on: A) overall positivity; B) categorized age; C) birth in a foreign country; D) Bacillus Calmette-Guérin (BCG) vaccination. Prior TST results are plotted for comparison (dark blue column).
Figure 3Performance of the QFT-GIT in relation to Mantoux TST results. QFT-GIT = QuantiFERON®-TB Gold in Tube; TST = tuberculin skin test.
Agreement between QFT-GIT and TST, stratified by BCG vaccination status
| QFT-GIT, n (%) | ||||
| TST >5 mm | Positive | Negative | Agreement | |
| All subjects | Positive | 7 (4.9) | 33 (23.1) | Raw = 72.7% |
| Negative | 6 (4.2) | 97 (67.8) | ||
| BCG vaccinated | Positive | 3 (4.1) | 22 (30.1) | Raw = 64.4% |
| Negative | 4 (5.5) | 44 (60.3) | κ = 0.04 | |
| No BCG | Positive | 3 (5.4) | 7 (12.5) | Raw = 85.8% |
| Negative | 1 (1.8) | 45 (80.4) | ||
| TST >10 mm | Positive | Negative | Agreement | |
| All subjects | Positive | 7 (4.9) | 22 (15.4) | Raw = 79.7% |
| Negative | 6 (4.2) | 108 (75.5) | ||
| BCG vaccinated | Positive | 3 (4.1) | 15 (20.5) | Raw = 74.0% |
| Negative | 4 (5.5) | 51 (69.9) | κ = 0.12 | |
| No BCG | Positive | 2 (3.6) | 3 (5.4) | Raw = 91.1% |
| Negative | 2 (3.6) | 49 (87.5) | ||
Kappa (κ) values with statistically significant p values are printed bold. P values for TST >5 mm: All subjects, p = 0.048; BCG vaccinated, p = 0.69; no BCG, p = 0.016. P values for TST >10 mm: All subjects, p = 0.021; BCG vaccinated, p = 0.35; No BCG, p = 0.036. BCG = Bacillus Calmette-Guérin; QFT-GIT = QuantiFERON®-TB Gold in Tube; TST = tuberculin skin test.
Multiple logistic regression analysis for positive TST and QFT-GIT results
| QFT-GIT ≥ 0.35 IU/ml | TST > 5 mm | TST > 10 mm | |
| Variables | Adjusted OR (95% CI) | Adjusted OR (95% CI) | Adjusted OR (95% CI) |
| Male sex | 1.0 (0.27–3.51) | 1.1 (0.48–2.61) | 1.5 (0.56–3.89) |
| Age categorized* | 1.6 (1.00–2.69)# | 1.6 (0.90–2.82)# | |
| Foreign birth country | 2.5 (0.67–9.42) | ||
| BCG vaccination | 1.7 (0.44–6.36) | ||
| Unknown BCG status | 2.4 (0.36–16.20) | 1.4 (0.31–6.32)# | 2.6 (0.51–13.33)# |
| Exposure per hour | 1.0 (0.95–1.07) | 1.0 (0.93–1.02) | 1.0 (0.95–1.04) |
| Close contact | 0.7 (0.22–2.41) | 1.0 (0.45–2.26) | 2.0 (0.74–5.29) |
| Nursing profession/Physician | 1.4 (0.44–4.75) | 0.7 (0.31–1.54) | 0.7 (0.30–1.83) |
| Affiliation with Pulmonary Care | 0.8 (0.09–6.76) | 0.5 (0.14–2.04) | 0.5 (0.09–2.50) |
| Family history of TB | 2.9 (0.46–18.01) | 3.8 (0.83–17.63) | 2.0 (0.40–10.16) |
* Compare Table 1. # Variable included in final model building. OR and 95% CI with statistical significance are printed bold. BCG = Bacillus Calmette-Guérin; CI = confidence interval; OR = Odds ratio; QFT-GIT = QuantiFERON®-TB Gold in tube; TST = tuberculin skin test.